A comparison of the effect of glitazones on serum sialic acid in patients with type 2 diabetes

Abstract

Although management of hyperglycaemia represents one of the principal treatment goals of diabetes therapy, the high incidence of cardiovascular (CV) complications in diabetes also needs effective management. Therefore, the present study was designed to determine and compare the effect of glitazones on serum sialic acid (SSA), a known risk marker for CV disease, along with fasting plasma glucose (FPG), glycohaemoglobin (HbA1-c) and blood lipids, in overweight, previously only diet-treated patients with type 2 diabetes (n=60). The study was conducted for a period of 12 months. Significant improvement in FPG and HbA1-c were shown by both rosiglitazone (p<0.003 and p<0.001, respectively) and pioglitazone (p<0.005 and p<0.001, respectively), compared with baseline, and pioglitazone showed greater beneficial effects on other parameters monitored, significantly reducing total cholesterol (TC) (p≤0.05). Both the drugs showed a decrease in SSA and no significant differences were observed between the groups. However, the decrease was significant only in the pioglitazone-treated group at month 12 (p≤0.05), compared with baseline. A significant decrease in SSA by pioglitazone indicates its greater cardioprotective effect compared with rosiglitazone.

Serum Levels of Glycoproteins are Elevated in Patients with Ovarian Cancer

“…The level of different types of serum glycoproteins are maintained within a narrow range in health [10], but is elevated in many pathological conditions viz. tuberculosis [11], autoimmune disease [12], cardiovascular disease [13,14], diabetes mellitus [15], cancer of cervix [16], uterus [17] and breasts [18], and arthritis [19]. Thus, it is of great interest to identify and validate serum glycoproteins whose change in levels may provide new insight into cancer progression and may have utility as potential markers for cancer diagnosis.…”

Biomarkers in follow-up treatment of alcoholism with hepatic comorbidity. An observational study

“…Assessing the results of the biomarkers GGT, TGP, GOT, in relation to the reference interval of biomarkers for determining the polarization of the sample on the critical area and highlighting the impact difference of polarization for alcoholic patients as compared to patients with associated alcoholic hepatopathy. 4. Building an econometric model on the data resulted, based on the smallest squares method for assessing the impact of alcoholism on changes in the biological markers (patients with hepatopathy associated with alcoholism vs. total patients with alcoholism).…”

“…According to WHO (1), worldwide consumption in 2010 was equal to 6.2 litres of pure alcohol per year consumed by people over 15 years of age, which translates to about 13.5 grams of pure alcohol per day (2,3). In Romania, the average consumption per capita in 2010 was 14.4 litres per year, while the European average was 10.9 litres per capita (1,2,4).…”

Protein biomarkers of alcohol abuse

“…Although these methods are relatively simple, their use is not widespread in clinical laboratories [29]. Furthermore, some cancers [34], cardiovascular disease [35] and other pathologies [36,37] can also result in increased serum TSA. Free sialic acid has also been investigated as a biomarker for alcohol abuse, but it was not found to be a better marker than TSA [31].…”